State-of-the Art Therapy for Gastrointestinal Stromal Tumors

References

• Fletcher, C D.M.; Berman, J J.; Corless, C L.; Gorstein, F.; Lasota, J.; Longley, B J.; Miettinen, M.; O'Leary, T J.; Remotti, H.; Rubin, B P.; Shmookler, B.; Sobin, L H.; Weiss, S W. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol. 2002, 33 (5), 459–465. [CSA]
   PubMed Web of Science ®Google Scholar
• Bauer, S.; Corless, C L.; Heinrich, M C.; Dirsch, O.; Antoch, G.; Kanja, J.; Seeber, S.; Schutte, J. Response to Imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother. Pharmacol. 2003, 51 (3), 261–265. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Plaat, B E.C.; Hollema, H.; Molenaar, W M.; Broers, G H.T.; Pijpe, J.; Mastik, M F.; Hoekstra, H J.; van den Berg, E.; Scheper, R J.; van der Graaf, W T.A. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins. J. Clin. Oncol. 2000, 18 (18), 3211–3220. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Duensing, A.; Medeiros, F.; Joseph, N E.; McConarty, B.; Yu, L K.; Liu, C.; Singer, S.; Fletcher, C D.M.; Demetri, G D.; Fletcher, J A. Oncogenic KIT signaling in gastrointestinal stromal tumors (GISTs). Proc. Am. Assoc. Cancer Res. 2003, 44, 1114.
   Google Scholar
• Kindblom, L G (2003) . In Gastrointestinal Stromal Tumors: Diagnosis, Epidemiology, Prognosis, Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June, 2003; .
   Google Scholar
• Miettinen, M.; El-Rifai, W.; Sobin, L H.; Lasota, J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol. 2002, 33 (5), 478–483. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• DeMatteo, R P.; Lewis, J J.; Leung, D.; Mudan, S S.; Woodruff, J M.; Brennan, M F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000, 231 (1), 51–58. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• DeMatteo, R P.; Maki, R G.; Antonescu, C.; Brennan, M F. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr. Probl. Surg. 2003, 40 (3), 144–193. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Roberts, J P.; Eisenberg, B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur. J. Cancer 2002, 38 (Suppl 5), S37–S38. [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Langer, C.; Gunawan, B.; Schuler, P.; Huber, W.; Fuzesi, L.; Becker, H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumors. Br. J. Surg. 2003, 90 (3), 332–339. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ng, E H.; Pollock, R E.; Munsell, M F. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging. Ann. Surg. 1992, 215, 68–77. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Mudan, S S.; Conlon, K C.; Woodruff, J M.; Lewis, J J.; Brennan, M F. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000, 88 (1), 66–74. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Matthews, B D.; Walsh, R M.; Kercher, K W.; Sing, R F.; Pratt, B L.; Answini, G A.; Henifor, B T. Laparoscopic vs. open resection of gastric stromal tumors. Surg. Endosc. 2002, 16 (5), 803–807. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gunter, E.; Lingenfelser, T.; Eitelbach, F.; Muller, H.; Ell, C. EUS-guided ethanol injection for treatment of a GI stromal tumor. Gastrointest. Endosc. 2003, 57 (1), 113–115. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kojima, T.; Takahashi, H.; Parra-Blanco, A.; Kohsen, K.; Fujita, R. Diagnosis of submucosal tumor of the upper GI tract by endoscopic resection. Gastrointest. Endosc. 1999, 50 (4), 516–522. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mavligit, G M.; Zukwiski, A A.; Ellis, L M.; Chuang, V P.; Wallace, S. Gastrointestinal leiomyosarcoma metastatic to the liver: durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 1995, 75 (8), 2083–2088. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Edmonson, J H.; Marks, R S.; Buckner, J C.; Mahoney, M R. Contrastof response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Investig. 2002, 20, 605–612. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Frustaci, S.; Foladore, S.; Buonadonna, A.; De Paoli, A.; Crivellari, D.; Carbone, A.; Sorio, R.; Morassut, S.; Monfardini, S. Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann. Oncol. 1993, 4 (8), 669–672. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Patel, S R.; Gandhi, V.; Jenkins, J.; Papadopolous, N.; Burgess, M A.; Plager, C.; Plunkett, W.; Benjamin, R S. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J. Clin. Oncol. 2001, 19 (15), 3483–3489. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Balcerzak, S P.; Benedetti, J.; Weiss, G R.; Natale, R B. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. Cancer 1995, 76 (11), 2248–2252. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Verweij, J.; Lee, S M.; Ruka, W.; Buesa, J.; Coleman, R.; van Hoessel, R.; Seynaeve, C.; de Paola, M.; van Glabbeke, D.; Tonelli, I R. Randomized phase II study of docetaxel versus doxorubicin in first-and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J. Clin. Oncol. 2000, 18 (10), 2081–2086. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Blair, S C.; Zalupski, M M.; Baker, L H. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am. J. Clin. Oncol. 1994, 17, 480–484. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Elias, A.; Ryan, L.; Sulkes, A.; Collins, J.; Aisner, J.; Antman, K H. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J. Clin. Oncol. 1989, 7, 1208–1216. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Zalupski, M.; Metch, B.; Balcerzak, S.; Fletcher, W S.; Chapman, R.; Bonnet, J D.; Weiss, G R.; Ryan, J.; Benjamin, R S.; Baker, L H. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a southwest oncology group study. J. Natl. Cancer Inst. 1991, 83 (13), 926–932. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ryan, D P.; Puchalski, T.; Supko, J G.; Harmon, D.; Maki, R.; Garcia-Carbonero, R.; Kuhlman, C.; Winnkelman, J.; Merriam, P.; Quigley, T.; Jimeno, J.; Manola, J.; Demetri, G D. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002, 7, 531–538. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• DePas, T.; Casali, P G.; Toma, S.; Romanini, A.; Massidda, B.; Comandone, A.; Labianca, R.; Massacesi, C.; Tucci, A.; Antimi, M.; Biasco, G.; Aglietta, M.; Apice, G.; deBraud, F. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? Oncology 2003, 64, 186–188. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eilber, F C.; Rosen, G.; Forscher, C.; Nelson, D J.; Dorey, F J.; Eilber, F R. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann. Surg. Oncol. 1999, 6, 645–650. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heinrich, M C.; Blanke, C D.; Druker, B J.; Corless, C L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002, 20 (6), 1692–1703. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mauro, M J.; O'Dwyer, M.; Heinrich, M C.; Druker, B J. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 2002, 20 (1), 325–334. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Joensuu, H.; Roberts, P J.; Sarlomo-Rikala, M.; Andersson, L C.; Tervahartiala, P.; Tuveson, D.; Silberman, S L.; Capdeville, R.; Dimitrijevic, S.; Druker, B.; Demetri, G D. Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001, 344 (14), 1052–1056. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• van Oosterom, A T.; Judson, I R.; Verweij, J.; Stroobants, S.; Dumez, H.; de Paola, E D.; Sciot, R.; Van Glabbeke, M.; Dimitrijevic, S.; Nielsen, O S. Update of phase I study of Imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 2002, 38 (Suppl 5), S83–S87. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Demetri, G D.; von Mehren, M.; Blanke, C D.; van den Abbeele, A D.; Eisenberg, B.; Roberts, P J.; Heinrich, M C.; Tuveson, D A.; Singer, S.; Janicek, M.; Fletcher, J A.; Silverman, S G.; Silberman, S L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B J.; Corless, C.; Fletcher, C D.M.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347 (7), 472–480. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• von Mehren, M.; Blanke, C D.; Joensuu, H.; Heinrich, M C.; Roberts, P.; Eisenberg, B.; Silberman, S.; Dimitrijevic, S.; Kiese, B.; Fletcher, J.; Fletcher, C.; Demetri, G D. High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors. Proc. Am. Soc. Clin. Oncol. 2002, 21 (1608), 403a.
   Google Scholar
• Verweij, J.; van Oosterom, A.; Blay, J Y.; Judson, I.; Rodenhuis, S.; van der Graaf, W.; Radford, J.; Le Cesne, A.; Hogendoorn, P C.W.; di Paola, E D.; Brown, M.; Nielsen, O S. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC soft tissue and bone sarcoma group phase II study. Eur. J. Cancer 2003, 39 (14), 2006–2011. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Benjamin, R S.; Rankin, C.; Fletcher, C.; Blanke, C.; von Mehren, M.; Maki, R.; Bramwell, V.; Baker, L.; Borden, E.; Demetri, G D. Phase III dose-randomized study of Imatinib mesylate (STI 571) for GIST: intergroup S0033 early results. Proc. Am. Soc. Clin. Oncol. 2003, 22 (3271), 814.
   Google Scholar
• Verweij, J.; Casali, P G.; Zalcberg, J.; Le Cesne, A.; Reichard, P.; Blay, J Y.; Issels, R D.; Van Glabbeke, M.; Di Paola, E D.; Judson, I R. Early efficacy comparison of two doses of Imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc. Am. Soc. Clin. Oncol. 2003, 22 (3272), 814.
   Google Scholar
• Heinrich, M C.; Corless, C L.; von Mehren, M.; Joensuu, H.; Demetri, G D.; Blanke, C D.; Dimitrijevic, S.; Kiese, B.; Fletcher, C D.M.; Fletcher, J A. PDGFRA and KIT mutations correlate with the clinical responses to Imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST). Proc. Am. Soc. Clin. Oncol. 2003, 22 (3274), 815.
   Google Scholar
• Fletcher, J A.; Corless, C L.; Dimitrijevic, S.; von Mehren, M.; Eisenberg, B.; Joensuu, H.; Fletcher, C D.M.; Blanke, C D.; Demetri, G D.; Heinrich, M C. Mechanisms of resistance to Imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc. Am. Soc. Clin. Oncol. 2003, 22 (3275), 815.
   Google Scholar
• Demetri, G D.; George, S.; Heinrich, M C.; Fletcher, J A.; Fletcher, C D.M.; Desai, J.; Cohen, D P.; Scigalla, P.; Cherrington, J M.; van den Abbeele, A D. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc. Am. Soc. Clin. Oncol. 2003, 22 (3273), 814.
   Google Scholar
• Nilsson, B E.; Bumming, P.; Meis-Kindblom, J M.; Kindblom, L G.; Engstrom, K.; Wangberg, B.; Jansson, S.; Ahlman, H. Treatment of gastrointestinal stromal tumors (GISTs) with Imatinib in neoadjuvant, adjuvant and palliative settings, a centre-based study of 17 patients. Proc. Am. Soc. Clin. Oncol. 2003, 22 (3337), 830.
   Google Scholar
• http://www.acosog.org
   Google Scholar
• http://www.RTOG.org
   Google Scholar